NewAmsterdam Pharma to Attend Investor Conferences in June 2024

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a biopharmaceutical firm in the late stages of clinical development, focuses on creating oral, non-statin drugs for patients at risk of cardiovascular disease (CVD) who have high levels of low-density lipoprotein cholesterol (LDL-C). These patients often find existing treatments ineffective or intolerable. The company has recently confirmed its participation in two significant investor conferences.

The first event is the Jefferies Global Healthcare Conference, which will take place in New York City on June 5, 2024. Michael Davidson, M.D., the Chief Executive Officer, and Ian Somaiya, the Chief Financial Officer, will be representing the company. They are scheduled to engage in a fireside chat at 3:00 p.m. ET.

The second event is the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10, 2024, in Miami Beach. Here, Michael Davidson, M.D., will deliver a corporate overview presentation at 10:40 a.m. ET.

Both presentations will be accessible via live webcasts, available through the investor relations section of NewAmsterdam Pharma's website. Archived replays of these webcasts will also be available online following the live presentations.

NewAmsterdam Pharma aims to enhance patient care for those with metabolic diseases where approved therapies fall short, either due to inefficacy or poor tolerance. Their primary focus is on developing a safe, well-tolerated, and convenient therapy for lowering LDL-C levels. The company’s leading product candidate, obicetrapib, is an oral, low-dose CETP inhibitor taken once daily. This drug is being evaluated, both alone and in combination with ezetimibe, in multiple phase 3 studies as an adjunct therapy to statins for patients with elevated LDL-C levels at risk of CVD.

The company is dedicated to addressing the significant unmet need in the market for effective and tolerable LDL-lowering therapies. Their goal is to develop an alternative for patients who do not respond well to current treatment options.

In summary, NewAmsterdam Pharma is making strides in the biopharmaceutical field with its innovative approach to treating high LDL-C in patients at risk for CVD. The company will share its progress and future plans at the upcoming Jefferies Global Healthcare Conference and Goldman Sachs 45th Annual Global Healthcare Conference. These presentations are significant opportunities for stakeholders to gain insights into the company’s strategies and advancements.